Free Trial
→ Louis Navellier: My #1 AI stock for 2026 (name & ticker inside) (From InvestorPlace) (Ad)tc pixel
NASDAQ:HELP

Cybin Q1 2025 Earnings Report

Cybin logo
$4.15 -0.28 (-6.32%)
Closing price 04:00 PM Eastern
Extended Trading
$4.10 -0.05 (-1.20%)
As of 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Cybin EPS Results

Actual EPS
-$0.01
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Cybin Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Cybin Announcement Details

Quarter
Q1 2025
Date
8/8/2024
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Cybin Earnings Headlines

Helus Pharma to Participate in the Jefferies Global Healthcare Conference in New York
June 1, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/01/3304254/0/en/helus-pharma-to-participate-in-the-jefferies-global-healthcare-conference-in-new-york.html
CORRECTION: Helus Pharma Partners with TARA Mind to Advance Veteran Mental Health
April 30, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/30/3285629/0/en/correction-helus-pharma-partners-with-tara-mind-to-advance-veteran-mental-health.html
Goldman Sachs just told you what to buy (most people missed it)
Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - not chips, not funding, but power. Demand is growing 15% per year and the grid can't keep up. One small company makes the exact equipment these data centers need. They're sitting on $1.5 billion in orders, their hardware is already inside Musk's Colossus, and the stock still trades like a name nobody's heard of. Analyst Dylan Jovine is releasing the ticker for free.tc pixel
June 5 at 1:00 AM  |  Behind the Markets (Ad)
Helus Pharma to Participate at the 29th Annual Milken Institute Global Conference
April 30, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/30/3284731/0/en/helus-pharma-to-participate-at-the-29th-annual-milken-institute-global-conference.html
Helus Pharma Partners with TARA Mind to Advance Veteran Mental Health
April 28, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/28/3282483/0/en/helus-pharma-partners-with-tara-mind-to-advance-veteran-mental-health.html
Does Robert Langer’s Arrival Reframe Confidence in Cybin’s (HELP) Clinical Strategy and Execution Risk?
April 25, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/does-robert-langer-arrival-reframe-120533038.html
See More Cybin Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cybin? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cybin and other key companies, straight to your email.

About Cybin

Cybin (NASDAQ:HELP) is a clinical-stage biopharmaceutical company focused on the development of psychedelic-based therapeutics for the treatment of mental health disorders. Headquartered in Toronto and listed on the NASDAQ under the symbol HELP, Cybin pursues research and development programs intended to harness the therapeutic potential of psychedelic compounds to address conditions with significant unmet need.

The company operates a drug discovery and development platform aimed at creating novel small-molecule psychedelic analogs and tailored formulations. Cybin’s work spans preclinical research through clinical trials, with an emphasis on optimizing pharmacology, dosing and delivery to improve safety, tolerability and the patient experience. Its R&D approach combines chemistry, formulation science and clinical development to advance candidate therapies toward regulatory review.

Cybin’s therapeutic efforts target a range of mental health indications that commonly include mood and anxiety disorders and substance-use disorders. The company pursues both internal development programs and collaborative relationships with academic and industry partners to support clinical development, regulatory strategy and potential commercialization pathways.

As a publicly traded biotechnology company, Cybin’s operations encompass research and development activities across multiple jurisdictions, with clinical programs conducted in regions where regulatory frameworks permit investigational studies of psychedelic-assisted treatments. The company positions itself to expand therapeutic options for patients and to contribute to the evolving scientific and clinical understanding of psychedelic-derived medicines.

View Cybin Profile
Earnings Tools